Acute rejection episodes after kidney transplantation

Area of Science:

• Nephrology
• Transplantation Immunology
• Clinical Medicine

Background:

• Acute rejection episodes (AREs) are a primary threat to renal allograft longevity.
• Recent advancements in immunosuppressive therapies have contributed to improved transplant outcomes.

Purpose of the Study:

• To investigate the incidence, severity, and risk factors of AREs.
• To evaluate the impact of AREs on graft and patient survival in kidney transplant recipients.

Main Methods:

• Retrospective analysis of 280 adult kidney transplants performed between 1986 and 2004.
• Diagnosis of AREs based on clinical data, treatment response, and limited allograft biopsies.
• Treatment involved pulse methylprednisolone and anti-thymocyte globulin.

Main Results:

• The overall incidence of AREs was 40.4%, with a notable decrease from >45% (1986-1997) to 9% (2001-2004).
• Graft survival rates at 10 years were 73% for patients with AREs versus 83% for those without.
• Reduced ARE incidence correlated with the introduction of sensitized cross-match and newer immunosuppressants like MMF.

Conclusions:

• A significant decline in ARE incidence was observed, linked to improved immunosuppressive strategies and pre-transplant screening.
• Despite treatment advancements, AREs negatively affect long-term kidney allograft survival.
• Continued research into optimizing immunosuppression and rejection prophylaxis is crucial for enhancing transplant success.